There are currently 27 ongoing clinical trials involving Keratoconus
Of the 27 trials,8 trials are in Phase III
Furthermore, 7 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Keratoconus, an Ophthalmology condition. The largest number of ongoing clinical trials for Keratoconus is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Keratoconus-related drug trials.
The Cornea and Laser Eye Institute PA: The leading ongoing Keratoconus related clinical trial sponsor
The Cornea and Laser Eye Institute PA is the top sponsor for Keratoconus-related ongoing clinical trials.
Cornea Associates of Texas PA, Corneal Consultants of Colorado Inc, Price Vision Group, Region Skane, and Sahlgrenska University Hospital are among other notable clinical trial sponsors involved in Keratoconus. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Keratoconus
Prednisolone sodium phosphate (Solone, Prednisolone, Minims Prednisolone Sodium Phosphate), and Riboflavin 5- phosphate sodium (Photrexa Viscous, Photrexa) are the two key marketed drugs involving Keratoconus.
Prednisolone sodium phosphate (Solone, Prednisolone, Minims Prednisolone Sodium Phosphate) is a glucocorticoid, anti-inflammatory agent, an antineoplastic agent. It functions via the Glucocorticoid Receptor Agonist mechanism of action. It is formulated as solution/drops for ophthalmic administration and solution, tablets for oral route of administration. Prednisolone tablets are indicated in conditions like pemphigus Vulgaris, allergic dermatitis, exfoliative dermatitis, dermatitis herpetiformis, dermatitis medicamentosa, erythema multiforme; disseminated lupus erythematosus, dermatomyositis, polyarteritis nodosa; severe bronchial asthma and status asthmaticus, emphysema, pulmonary fibrosis; adrenal hyperplasia (adrenogenital syndrome); idiopathic thrombocytopenic purpura, acquired hemolytic anemia, acute leukemia; nephrotic syndrome; iridochoroiditis; ulcerative colitis; rheumatoid arthritis; ankylosing spondylitis, rheumatic fever, gout and periarthritis of the shoulder. Prednisolone sodium phosphate was first approved prior to 1982 and is marketed globally including the US, the UK, Canada, and Newzealand by Bausch Health US LLC.
Riboflavin 5- phosphate sodium (Photrexa Viscous, Photrexa) is a precursor of two coenzymes flavin adenine dinucleotide and flavin mononucleotide. Riboflavin is the precursor of flavin mononucleotide (FMN, riboflavin monophosphate) and flavin adenine dinucleotide (FAD). Photrexa is formulated as an ophthalmic solution for topical application. Photrexa Viscous, Photrexa is used for corneal collagen cross-linking in combination with the KXL system for the treatment of progressive keratoconus and for corneal ectasia following refractive surgery. Riboflavin 5-phosphate sodium is under development for the treatment of corneal ulcers in the U.S. Riboflavin 5- phosphate sodium was first approved in 2016 and is marketed in the US by Avedro Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer